Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 1.3% during trading on Friday . The stock traded as high as $7.20 and last traded at $7.11, with a volume of 427,881 shares trading hands. The stock had previously closed at $7.02.

Several equities research analysts recently commented on the stock. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research report on Sunday, June 12th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Friday, May 6th. Zacks Investment Research cut shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. Cowen and Company reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Friday, August 19th. Finally, Citigroup Inc. cut shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $6.00 to $8.00 in a research report on Monday, August 8th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $7.79.

The firm’s market cap is $620.17 million. The company has a 50 day moving average of $6.41 and a 200 day moving average of $5.20.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The firm had revenue of $32.05 million for the quarter, compared to analyst estimates of $28.52 million. During the same quarter last year, the company earned ($0.17) earnings per share. The company’s quarterly revenue was up 37.4% compared to the same quarter last year. Equities analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.91) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Schwab Charles Investment Management Inc. increased its position in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 3.3% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 292,620 shares of the company’s stock after buying an additional 9,354 shares during the period. Schwab Charles Investment Management Inc. owned 0.34% of Raptor Pharmaceutical Corp. worth $1,522,000 at the end of the most recent reporting period.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.